Condition: Multiple Myeloma · Sponsor: Bristol-Myers Squibb
The purpose of this study is to monitor the long-term safety of participants who received idecabtagene vicleucel treatment as part of the KarMMa-9 (CA089-1043) Phase 3 clinical trial.
This description comes directly from the study's public registry record.
BMS Study Connect Contact Center www.BMSStudyConnect.com · 855-907-3286 · Clinical.Trials@bms.com
First line of the email MUST contain NCT # and Site #.
Always discuss trial participation with your own doctor first.
| Chonnam National University Hwasun Hospital | Hwasun, Jeonranamdo, South Korea | Recruiting |
| Seoul National University Hospital | Seoul, Seoul-teukbyeolsi [Seoul], South Korea | Recruiting |
| Asan Medical Center | Seoul, Seoul-teukbyeolsi [Seoul], South Korea | Recruiting |
| Samsung Medical Center | Seoul, Seoul-teukbyeolsi [Seoul], South Korea | Recruiting |
| The Catholic Univ. of Korea Seoul St. Mary's Hospital | Seoul, Seoul-teukbyeolsi [Seoul], South Korea | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06698887